Allen R. Voigt, founder and CEO of EndoPure Life Sciences, believes that trust has become the defining issue for the next ...

This Illinois spa retreat brings robes, warm water, quiet views, and the kind of reset that makes regular life feel very far ...

Avecho shares today entered trading halt, pending the release of results for the company's synthetic cannabinoid phase III ...

It's the most widely studied sleep aid in children, but many parents still feel uncertain or even guilty about using it ...

Over 90 years ago, Hans Selye challenged the notion that stress is inherently negative. He argued that stress is a natural ...

Cannabidiol (CBD) is a naturally occurring compound found in cannabis, thought to have beneficial effects on things like ...

Canopy Growth (NASDAQ:CGC) operates in the Nasdaq Composite cannabis sector with diversified products including beverages, ...

Digital healthcare has reshaped how patients access physicians, manage chronic conditions, and make decisions about their ...

Researchers at the Federal University of São Paulo (UNIFESP) in Brazil have identified a molecule on the surface of cells that could be a promising therapeutic target against cancer.

UK-based Ananda Pharma has announced successful completion of its Phase 1 pharmacokinetic study of its MRX1 cannabidiol oral solution to treat chronic pain conditions, with all study objectives met.

Ananda Pharma Limited is a UK pharmaceutical company developing regulatory approved cannabidiol medicines to treat complex, chronic conditions.